Scarica l'app Stockscreener
46.07
6.87%
-3.40
Dopo l'orario di chiusura:
47.00
0.93
+2.02%
Precedente Chiudi:
$49.47
Aprire:
$49.14
Volume 24 ore:
1.01M
Relative Volume:
0.70
Capitalizzazione di mercato:
$1.95B
Reddito:
-
Utile/perdita netta:
$-63.78M
Rapporto P/E:
-17.19
EPS:
-2.68
Flusso di cassa netto:
$-53.91M
1 W Prestazione:
-8.79%
1M Prestazione:
-17.63%
6M Prestazione:
+432.60%
1 anno Prestazione:
+217.72%
Intervallo 1D:
$45.85
$49.98
Intervallo di 1 settimana:
$45.85
$50.63
Portata 52W:
$7.575
$63.06
Celcuity Inc Stock (CELC) Company Profile
Nome
Celcuity Inc
Settore
Industria
Telefono
763-392-0767
Indirizzo
16305 36TH AVENUE N, MINNEAPOLIS, MN
Confronta CELC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
46.07 | 2.10B | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-22 | Iniziato | Guggenheim | Buy |
| 2025-07-01 | Ripresa | Stifel | Buy |
| 2024-07-22 | Iniziato | Leerink Partners | Outperform |
| 2024-02-22 | Iniziato | Stifel | Buy |
| 2023-12-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-08 | Iniziato | Canaccord Genuity | Buy |
| 2021-09-07 | Iniziato | Jefferies | Buy |
| 2021-07-29 | Iniziato | Cowen | Outperform |
| 2021-07-27 | Iniziato | Needham | Buy |
| 2021-01-28 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-11 | Ripresa | Craig Hallum | Buy |
| 2018-11-20 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Celcuity Inc Borsa (CELC) Ultime notizie
Celcuity (NASDAQ:CELC) Stock Price Down 5.1%What's Next? - MarketBeat
Historical volatility pattern of Celcuity Inc. visualizedJuly 2025 PostEarnings & Weekly Market Pulse Alerts - newser.com
Celcuity's (CELC) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Celcuity: Blink And You Missed It (NASDAQ:CELC) - Seeking Alpha
Celcuity's VIKTORIA-1 Results To Anchor ESMO Presentation; NDA Submission Underway - RTTNews
Short interest data insights for Celcuity Inc.Quarterly Investment Review & Weekly Watchlist of Top Performers - newser.com
What data driven models say about Celcuity Inc.’s futureTrade Exit Report & Safe Capital Growth Tips - newser.com
Multi asset correlation models including Celcuity Inc.Weekly Loss Report & Weekly Sector Rotation Insights - newser.com
Celcuity Inc. stock trend forecastStop Loss & Daily Stock Trend Reports - newser.com
Long term hold vs stop loss in Celcuity Inc.Layoff News & Daily Growth Stock Investment Tips - newser.com
Can technical indicators confirm Celcuity Inc.’s reversal2025 Trade Ideas & Daily Oversold Stock Bounce Ideas - newser.com
Should FDA Real-Time Review of Gedatolisib Prompt a Closer Look From Celcuity (CELC) Investors? - simplywall.st
Needham Maintains Celcuity(CELC.US) With Buy Rating, Maintains Target Price $70 - 富途牛牛
Celcuity (NASDAQ:CELC) Given Buy Rating at Needham & Company LLC - MarketBeat
How to interpret RSI for Celcuity Inc. stock2025 Institutional Moves & Daily Stock Momentum Reports - newser.com
Celcuity (CELC): Valuing the Stock After FDA Acceptance of Gedatolisib and Major Pipeline Progress - Sahm
Celcuity Expands Credit Facility to $500 Million - MSN
Why Celcuity Inc. stock appeals to dividend seekers2025 Technical Overview & Smart Investment Allocation Insights - newser.com
Celcuity (NASDAQ:CELC) Shares Down 4.8%Here's Why - MarketBeat
3 Growth Companies With High Insider Ownership Seeing Up To 63% Revenue Growth - simplywall.st
Celcuity Inc. (CELC)’s FDA NDA for Gedatolisib Accepted Under RTOR, Accelerating Review - Insider Monkey
Certain Options of Celcuity Inc. are subject to a Lock-Up Agreement Ending on 29-SEP-2025. - MarketScreener
Certain Pre-Funded Warrants of Celcuity Inc. are subject to a Lock-Up Agreement Ending on 29-SEP-2025. - MarketScreener
Certain Common Stock of Celcuity Inc. are subject to a Lock-Up Agreement Ending on 29-SEP-2025. - MarketScreener
Craig-Hallum Remains a Buy on Celcuity (CELC) - The Globe and Mail
The Bull Case For Celcuity (CELC) Could Change Following Expanded Credit Facility and Rising Commercial Ambitions - simplywall.st
Celcuity (NASDAQ:CELC) Shares Down 5.5%Time to Sell? - MarketBeat
Celcuity to present phase 3 breast cancer trial data at ESMO congress - Investing.com Nigeria
Goldman Sachs Group Inc. Sells 28,686 Shares of Celcuity, Inc. $CELC - MarketBeat
Guggenheim initiates Celcuity stock with Buy rating on breast cancer drug potential By Investing.com - Investing.com South Africa
Guggenheim initiates Celcuity stock with Buy rating on breast cancer drug potential - Investing.com Australia
Guggenheim Maintains Celcuity(CELC.US) With Buy Rating, Raises Target Price to $110 - 富途牛牛
Celcuity Inc Azioni (CELC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Celcuity Inc Azioni (CELC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Dalvey David | Director |
Jul 28 '25 |
Sale |
43.98 |
100,000 |
4,397,603 |
125,000 |
| Dalvey David | Director |
Jul 28 '25 |
Sale |
45.12 |
9,325 |
420,767 |
0 |
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):